Volume Spike Investor

Human Genome Sciences Inc. (HGSI) is getting clipped in early trading but volume is still rather light. This one has risen sharply in recent days that its Lupus drug partner GSK was interested in buying the company outright. There has not been a total rebuff or denial, but these reports seem to be getting dismissed [...]

We are seeing many unusual winners and losers today on exponential trading volume gains.  Five of the more unusual movers on strong volume as of 3:20 PM EST today are as follows: Eastman Kodak Co. (NYSE: EK), The Hain Celestial Group, Inc. (NASDAQ: HAIN), Human Genome Sciences Inc. (NASDAQ: HGSI), SIRIUS XM Radio Inc. (NASDAQ: [...]

Human Genome Sciences Inc. (NYSE: HGSI) is trading up yet again, and on the same news… or at least the same takeover hopes.  At 8:48 AM EST we have seen shares up yet another 11% to multi-year highs yet again of $21.40… The 52-week range is $0.35 to $19.98.  The volume is now over 800,000 [...]

Human Genome Sciences, Inc. 9NASDAQ: HGSI) is surging on two bits of data which may be more round-about rather than direct on the company. First, there was some chatter of a potential takeover yesterday but that is common in biotech and related stocks from time to time. Second, the Obama administration has pledged to help [...]

Human Genome Sciences, Inc. (NASDAQ: HGSI) is seeing unusual trading volume and price action this morning.  The genomics company was Raised to Buy at ThinkEquity.  We have shares up 4.2% at $14.85 on over 120,000 shares at 8:08 AM EST.  This one trades close to 10 million shares on an average day but it is [...]

Human Genome Sciences Inc. (Nasdaq: HGSI) shares are up nearly 4 percent to $14.39 in premarket trading of about 34,000 shares as of 7:30 a.m. Eastern. The company said the U.S. government has ordered an additional 45,000 doses of the company’s Abthrax vaccine to add to the Strategic National Stockpile. The company expects to receive [...]

Human Genome Sciences Inc. (Nasdaq: HGSI) shares are up 17 percent to $14.72, on about 10 times average volume. The company late Monday said its Benlysta lupus treatment candidate met its primary and secondary endpoints. Analysts at ThinkEquity said the data favor approval, which could make it the first FDA-approved lupus therapy in more than [...]

Human Genome Sciences Inc. (NASDAQ: HGSI) is going to be the top price leader this morning.  It and GlaxoSmithKline (GSK) have announced that the BENLYSTA study met the primary endpoint in BLISS-52, the first of two pivotal Phase III trials in patients with serologically active systemic lupus. HGSI shares closed at $3.32 Friday, yet the [...]

Human Genome Sciences Inc. (Nasdaq: HGSI) shares are up more than 6 percent to $2.55 on volume of more than 120,000 shares as of about 8:30 a.m. Eastern. The company says data published in The New England Journal of Medicine supports the use of its human monoclonal antibody drug Raxibacumab for the treatment of inhalation [...]

Human Genome Sciences Inc. (HGSI) gave positive data on its Lupus studies.  This showed that Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy.  In early trading at 7:59 AM EST shares up 15% or so pre-market from $2.71 close to $3.15 in early [...]